Background: The prevalence of left ventricular hypertrophy (LVH) is frequent in 28
Introduction 48 49
Cardiac hypertrophy is one of the most common cardiac abnormalities in uremic 50 patients and represents a leading cause of death (38) . Experimental studies have also 51
shown similar cardiovascular abnormalities in nephrectomized rats, the animal model of 52 chronic uremia (16).
The classical hypertrophy inducers including endothelin, 53 catecholamines and angiotensin II (Ang II) are known to play a major role in clinical and 54 experimental uremia (3, 16). We and others have previously shown that uremic rats with 55 chronic renal failure develop significant cardiac hypertrophy (2, 16). Two important 56 mechanisms of cardiac hypertrophy have been described, which include glycogen 57 synthase kinase-3β (GSK-3β)/β-catenin and calcineurin/nuclear factor of activated T cells 58 the renal vessels and ureter were tied, and the right kidney was excised. The animals 115 were allowed to recover and the drug treatment was initiated 7 days later. 116
117
Experimental Groups: Rats were randomized into four groups (n=6/group) as shown in 118 Figure 1 . The control group underwent sham surgery, and the other 3 groups underwent 119 five-sixth nephrectomy as described above. Prior to surgery, the animals were kept 120 overnight in metabolic cages and urine was collected for determining proteinuria. The 121 animals were kept in the metabolic cages at the beginning of weeks 3, 5, and 7 for urine 122
collection. 123 124
Treatment protocol: Suspension of curcumin and enalapril were prepared in 0.5% 125 carboxymethylcellulose (CMC). Due to the instability of curcumin in the aqueous 126 solution, it was prepared fresh and was administered within 10 minutes of the 127 preparation. As shown in Fig 1, the nephrectomized (Nx) rats were randomized to receive 128 the following treatments. 1. Vehicle (0.5% CMC) which was administered by oral 129 gavage; 2. Curcumin at a dose of 150 mg/kg daily. 3. Enalpril (10 mg/kg, suspended in 130 CMC).
The control group consisted of sham operated rats where the capsule was 131 7
Echocardiography 138
Echocardiography was performed using the Vevo770 TM imaging system (VisualSonics 139
Inc., Toronto, Canada) prior to surgery (baseline) and 8 weeks after surgery prior to 140 sacrificing the animal. Pentobarbital (30 mg/kg; ip) was used for anesthesia and the 141 procedure was carried out as previously described (37) to measure LV end-diastolic 142 diameter (LVEDD) and end-systolic diameter (LVESD). Inferior vena cava (IVC) 143 diameter (in mm) was measured at end-inspiration by echocardiography using a subcostal 144 approach. This technique provides simple and useful measurements of IVC size and 145 function in cardiac disease (36), and is reflective of right atrial pressure which increases 146 with heart failure. 147
Measurement of blood urea nitrogen and creatinine: 148
Blood urea nitrogen (BUN) and creatinine were measured by a NOVA16 autoanalyzer 149 (NOVA Biomedical, Waltham, MA). 150
151

Longitudinal measurement of arterial pressure by tail plethysmography : 152
Arterial blood pressure (BP) was determined by tail plethysmography as stated before 153 (17), using the CODA 2 system (Kent Scientific Corporation, Torrington, CT ). CODA 2 154 utilizes volume pressure recording sensor technology to measure rat tail blood pressure. 155 This is a computerized, non-invasive tail cuff acquisition system which can 156 simultaneously measure systolic, diastolic and mean arterial pressure without operator0). During this period, 25 sequential readings were obtained. Values within a range of 10 160 mm Hg were averaged. Two weeks after the second surgery, the animals were retrained 161 and BP was recorded (week 2). Similar BP recording was done on weeks 5 and 8 post 162 blots confirmed the purity of nuclear extracts. A small aliquot of kidney homogenate, 181 cytosol and nuclear extract was used for protein estimation.
183
Immunoblotting: 184
The cytosol (75-100 µg total protein) and nuclear extracts (50 µg total protein) were 185 separated on a 4-20% SDS-PAGE gel, and proteins were transferred to a PVDF 186 membrane as described previously (16). After washing briefly in phosphate-buffered 187 saline containing 1% Tween-20 (PBS-T) and blocking in 5% nonfat dry milk, blots were 188 incubated with appropriate antibodies in 5% nonfat dry milk overnight at 4°C. The 189 membranes were washed 3-5 times in PBS-T, and subsequently incubated with 190 appropriate secondary antibody diluted in 5% nonfat dry milk for 1 h at room 191 temperature. After 3-5 washes in TBS, blots were developed using Lightning 192
Chemiluminescence Reagent Plus and exposed to X-ray film. Statistical comparisons among groups were performed using ANOVA followed by 215
Tukey's Multiple Comparison Test. Groups were considered to be significantly different 216 with a P value equal to, or less than, 0.05. 217
218
RESULTS
219
Effect of curcumin and enalapril on systolic blood pressure, proteinuria, plasma 220 creatinine and blood urea nitrogen: 221
222
As shown in table 1, the systolic blood pressure (SBP) of Nx animals measured at 3, 5, 223 and 7 weeks was significantly higher than control rats (p<0.01). Longitudinal 224 measurement of SBP showed that enalapril treatment effectively curtailed the increase in 225 SBP (p<0.01). Curcumin had no significant effect on SBP until the seventh week. 226
Subtotal nephrectomy resulted in renal dysfunction, as evidenced by gradual increase in 227 proteinuria (Table 1) , elevation in BUN and plasma creatinine measured at 8 weeks 228 (Table 2) .
Moreover, Nx animals demonstrated progressive increase in proteinuria. 229
Both curcumin and enalapril treatment significantly reduced proteinuria by 40-60%. The 230 proteinuria in curcumin and enalapril cohorts was not significantly different. BUN and 231 plasma creatinine were almost 4 fold higher in Nx animals than the vehicle control at 8 232 weeks. Curcumin was as effective as enalapril in reducing both the BUN and creatinine 233 levels (p<0.01). These data suggest that curcumin is as effective as enalapril in 234 attenuating renal dysfunction in NX animals. 235
236
Effect of nephrectomy on kidney weight: 237
Nephrectomized animals had their right kidney removed therefore the left kidney of the 238 control was compared with the 2/3 excised left kidney of the nephrectomized animals. 239
As shown in table 2 there was no significant difference in kidney weight between the 240 groups. However, it is to be noted that the control animals had intact kidney and the 241 partially ablated left kidney of the Nx group and treated animals (whose left kidney was 242 also partially ablated) had hypertrophied to compensate for the nephron loss. Therefore 243 there was no significant difference in the weight. 244
Effect of curcumin and enalapril on cardiac remodeling: 245
The body weight (BW) of curcumin and enalapril treated rats were lower by 17% and 246 21%, respectively, as compared with the corresponding vehicle control group (p<0.001, 247 Table 2 ). LV weight of control and Nx rats were not different i.e., 1.13±0.14 versus 1.34 248 ±0.24 g, p>0.05. LV weight in rats treated with curcumin and enalapril were lower as 249 compared with Nx (p<0.01). The LV/BW ratio for curcumin and enalapril-treatedanimals were not different from control, but they were significantly lower than Nx 251 animals (p<0.001). The average RV/BW of Nx animals was 1.7 fold higher than the 252 control (p<0.01). Both curcumin and enalapril treatment significantly improved RV/BW 253 ratio (p<0.05). 254 Figure 2A shows representative M-mode images from sham operated and Nx rats at 8 255 weeks. These images clearly show more dilatation and wall thickening in Nx rats as 256 compared with sham control. The average data (in mm) showed a significant increase in 257 LV mass in Nx rats (1.47±0.19) as compared with controls (0.98±0.04, P<0.01, Fig 2B) . 258
Curcumin and enalapril-treated rats had LV mass of 0.95±0.1 (P<0.01) and 0.93±0.3 259 (P<0.05), respectively. LV end diastolic diameter (EDD, in mm) was higher in Nx rats 260 (7.2±0.2) as compared to controls (6.4±0.2, P=0.01). Curcumin and enalapril attenuated 261 LV dilatation as shown by EDD of 6.3±0.5 and 6.2±0.5, respectively (P=0.01, Fig 2C) . 262
Using a subcostal approach, we also measured changes in inferior vena cava (IVC) 263 diameter at end-inspiration, which is a diagnostic tool for identification of increased right 264 atrial pressure and congestive heart failure.
As shown in Fig 3A, IVC diameter 265 decreased with inspiration in both the control and Nx rats. However, the IVC diameter at 266 end-inspiration was significantly higher in the Nx rats as compared to the sham control. 267
Furthermore, rats treated with curcumin or enalapril demonstrated significantly smaller 268 13 (29). Our results show no significant changes in GSK-3β mRNA (not shown) and non-273 phosphorylated GSK3β (total) protein between the groups (Fig 4A) . However, pGSK-3β 274 in Nx hearts was almost 2 fold higher as compared with the controls (Fig 4B p<0.001) . 275
Moreover, pGSK3β/GSK3β ratio was 2.2 fold higher in Nx (p<0.001) as compared to 276 controls demonstrating inactivation of the protein (Fig 4C) . A significantly lower pGSKβ 277 was observed in curcumin (44%, p<0.01) and enalapril (30%, p<0.05) treated animals. 278
Effect of curcumin and enalapril on β-Catenin expression: 279
β-catenin is a downstream target of GSK-3β and its overexpression is known to induce 280 cardiomyocyte growth in vivo and in vitro (20). β-catenin mRNA, measured by real time 281 PCR, was increased in Nx animals as compared to controls (p<0.05). Curcumin and 282 enalapril treatment had no effect on the mRNA levels ( Fig 5A) . The cytosolic β-catenin 283 was significantly higher in Nx animals as compared with controls (p<0.01), and was 284 reduced by curcumin treatment (p<0.05, Fig 5B) . Similarly, β-catenin was significantly 285 higher in the nuclear fractions as compared with controls (p<0.01, Fig 5C) , and was 286 decreased by curcumin. In the Nx animals, the β-catenin levels in total homogenates 287 were 1.4 fold higher than the controls but this was not statistically significant (data not 288 shown). Enalapril treatment had no significant effect on β-catenin protein expression. 289
Effect of curcumin and enalapril on calcineurin: 290
The calcium activated protein phosphatase, calcineurin, is a serine-threonine-specific 291 phosphatase which plays a central role in the development of pathological cardiac 292 hypertrophy (31). Ang II has been shown to activate calcineurin in various settings (40, 293 41). Calcineurin mRNA (measured by real time PCR) and protein expression were 294 increased in Nx animals (Fig 6A and 6B) , and decreased following treatment with 295 enalapril. However, curcumin had no effect on calcineurin mRNA or protein expression. 296
Effect of curcumin and enalapril on NFAT: 297
Dephosphorylation of NFAT facilitates its nuclear migration and enhanced DNA binding 298 leading to hypertrophy. Both calcineurin and GSK-3β are known to regulate NFAT 299 phosphorylation and hypertrophy (34, 47). In the present study, we did not observe a 300 significant difference in non-phosphorylated cytosolic NFAT between the groups (data 301 not shown). However, cytosolic phosphorylated NFAT (p-NFAT) was significantly 302 decreased in Nx animals compared to control ( Figure 7A ), and was significantly 303 attenuated by enalapril and curcumin (p<0.05). The NFAT in the nuclear fraction of Nx 304 animals was significantly higher as compared to the control ( Figure 7B , p<0.01), and was 305 decreased by curcumin (p<0.05) and enalapril (p<0.01). There was no significant 306 difference in the cytosolic and nuclear NFAT between curcumin and enalapril. We also 307 confirmed these results by using NFAT-DNA binding assay (TransAm™ transcription 308 factor ELISA). As shown in figure 7C , NFAT DNA binding was nearly two fold higher 309 than the control (p<0.01) and both curcumin and enalapril significantly decreased it 310 (p<0.05). 311
Both AKT and ERK modulate the phosphorylation of GSK3β and activation of 312 calcineurin-NFAT pathway (30, 43).
We investigated the role of these signaling 313 molecules in the Nx hearts and to see if curcumin and enalapril can modify their 314 phosphorylation state. The ratios of pERK/ERK (Fig 8A) and pAKT/AKT was 315 significantly higher in the Nx animals as compared to the controls (p<0.01, Fig 8B) .
Curcumin and enalapril significantly reduced the pERK and pAkt (p<0.01) without 317 affecting the non-phosphorylated proteins (Fig 8) . creatinine. Nx rats showed a significant hypertrophic response and increased end-332 inspiration IVC diameter, which were inhibited by treatment with curcumin and enalapril. 333
Moreover, the Nx rats demonstrated changes in the signaling molecules that are critically 334 involved in the hypertrophic response.
These included increased GSK-3β 335 phosphorylation, β-catenin expression, calcineurin, pNFAT, pERK as well as pAKT. 336
Both curcumin and enalapril effectively deactivated most of these pathways triggered by 337 nephrectomy in the heart. Taken together, these results demonstrate excellent protectiveeffect of curcumin, similar to enalapril, in attenuating cardiac hypertrophy in rats with 339 chronic renal failure. 340
In the present study we utilized 150 mg/kg/day curcumin which effectively reduced the 341 biochemical markers of renal dysfunction in the Nx group, similar to enalapril treatment. of Ser-9 by Akt appears to be the mechanism by which β-catenin is stabilized (20). The 376 cytoplasmic stabilized β-catenin enters the nucleus and regulates hypertrophic gene 377 expression (8, 42). It has been shown that targeted deletion of ß-catenin in the heart leads 378 to a blunted hypertrophic response to pathological stress-induced growth (11). Increased 379 cytosolic β-catenin is also observed in renal tubular epithelial cells following injury 380 initiated by unilateral ureteral obstruction (44). In the present study increased GSK-3β in 381 the Nx animals was associated with augmentation in cytosolic β-catenin suggesting 382 stabilization of the protein. This was followed by increased nuclear translocation of βdecreased the accumulation of cytosolic β-catenin and its subsequent migration to the 385 nucleus by blunting phosphorylation of GSK-3β. Furthermore, curcumin-mediated 386 breakdown of β-catenin (25) might also contribute to the reduced level of this protein in 387 the curcumin treated animals. Enalapril did not have any effect on β-catenin although it 388 reduced GSK-3β phosphorylation. The exact reason is not clear, but it has been shown 389 that Ang II was able to induce cardiac hypertrophy when inducible cardiomyocyte 390 specific deletion of the β-catenin gene was used. Accordingly it was suggested that β-391 catenin is not required for induction of cardiac hypertrophy induced by Ang II (5). 392
Moreover, it has been proposed that the effect of β-catenin on cardiac hypertrophy might 393 be dependent on the hypertrophic stimulus (7). corresponding increase in nuclear NFAT in Nx animals was observed. The increase of 416 dephosphorylated cytosolic NFAT in Nx animals appears to be due to increased 417 calcineurin and pGSK-3β seen in this group. Curcumin and enalapril increased the levels 418 of pNFAT in the cytosol and decreased its nuclear migration. It is to be noted that 419 enalapril blocked both calcineurin and phosphorylation of GSK-3β whereas curcumin 420 only affected GSK-3β. Consequently, we anticipated that the levels of pNFAT in 421 enalapril group would be higher than the curcumin-treated group. Although, the pNFAT 422 in the cytosol of enalapril animals was 21% higher than the curcumin, it was statistically 423 insignificant. Moreover, there was no significant change in nuclear translocation of 424 NFAT between the groups. Curcumin and enalapril neither affected the mRNA nor the 425 nonphosphorylated GSK-3β and NFAT suggesting that these compounds might affect 426 cardiac hypertrophy by post translational modification of these proteins. 
